FutureChem Co.,Ltd
KOSDAQ 220100.KQ
FutureChem Co.,Ltd Price to Sales Ratio (P/S) on January 14, 2025: 24.06
-
FutureChem Co.,Ltd 52-week high Price to Sales Ratio (P/S) is 46.40 on October 15, 2024, which is 92.82% above the current Price to Sales Ratio (P/S).
-
FutureChem Co.,Ltd 52-week low Price to Sales Ratio (P/S) is 13.41 on February 05, 2024, which is -44.28% below the current Price to Sales Ratio (P/S).
-
FutureChem Co.,Ltd average Price to Sales Ratio (P/S) for the last 52 weeks is 24.95.
| Date | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield |
|---|
| CEO | Mr. Dae-Yoon Chi |
| IPO Date | Dec. 1, 2016 |
| Location | South Korea |
| Headquarters | 21, Yeonmujang 3-gil |
| Employees | 67 |
| Sector | Health Care |
| Industries | |
FutureChem Co.,Ltd produces and sells radiopharmaceuticals in Korea. The company offers PDVUE, a positron emission tomography (PET) radiopharmaceutical diagnostic medicine for Parkinson's disease; Alzavue, a diagnostic medicine for Aalzheimer's disease; and [18F]FDG, a PET radiopharmaceutical for the treatment of cancer. Its products in pipeline include 18F-FC303, a diagnostic PET radiopharmaceuticals for the treatment of prostate cancer; 177Lu-FC705 for the treatment of prostate cancer; 18F-FMT for the treatment of brain tumor; 18F-FC505, for the treatment of atherosclerotic plaque; and 18F-FC211, for the treatment of Alzheimer's disease. FutureChem Co.,Ltd was founded in 1999 and is headquartered in Seoul, South Korea.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email